ARID1A and ovarian carcinoma: This conclusion is supported by the observation that restoring WT ARID1A expression in ovarian cancer cells harboring ARID1A mutations is sufficient to inhibit cell growth and tumor growth in xenotransplantation assays, while silencing of ARID1A expression in non-transformed ovarian epithelial cells is sufficient to stimulate cell proliferation and to induce tumorigenicity [139].